[{"x_label":"Diffuse intrinsic pontine glioma  (Dataset = PBTA, Specimen = Pediatric Relapse Tumors, N = 6)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":6,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"Diffuse intrinsic pontine glioma","GTEx_tissue_subgroup":"","EFO":"EFO_1000026","MONDO":"MONDO_0006033","GTEx_tissue_subgroup_UBERON":"","TPM_mean":6.96,"TPM_sd":1.69,"TPM_min":5.52,"TPM_25th_percentile":6.06,"TPM_median":6.43,"TPM_75th_percentile":7.04,"TPM_max":10.2},{"x_label":"Diffuse midline glioma  (Dataset = PBTA, Specimen = Pediatric Relapse Tumors, N = 48)","specimen_descriptor_fill":"Pediatric Relapse Tumors","box_sample_count":48,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"Diffuse midline glioma","GTEx_tissue_subgroup":"","EFO":"EFO_1000026","MONDO":"MONDO_0006033","GTEx_tissue_subgroup_UBERON":"","TPM_mean":10.95,"TPM_sd":14.18,"TPM_min":1.69,"TPM_25th_percentile":4.96,"TPM_median":6.77,"TPM_75th_percentile":9.99,"TPM_max":79.59},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 13)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":13,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.94,"TPM_sd":2.97,"TPM_min":0.99,"TPM_25th_percentile":3.9,"TPM_median":4.34,"TPM_75th_percentile":4.9,"TPM_max":12.09},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 14)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":14,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.03,"TPM_sd":1.37,"TPM_min":1.41,"TPM_25th_percentile":3.3,"TPM_median":3.98,"TPM_75th_percentile":4.79,"TPM_max":7.19},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 5)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":5,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.23,"TPM_sd":1.72,"TPM_min":1.63,"TPM_25th_percentile":3.39,"TPM_median":4.89,"TPM_75th_percentile":5.41,"TPM_max":5.84},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Relapse Tumors, N = 3)","specimen_descriptor_fill":"TCGA Relapse Tumors","box_sample_count":3,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.45,"TPM_sd":1.65,"TPM_min":2.79,"TPM_25th_percentile":3.63,"TPM_median":4.48,"TPM_75th_percentile":5.28,"TPM_max":6.08}]